| Literature DB >> 36077220 |
Nikolai A Lomov1, Vladimir S Viushkov1, Sergey V Ulianov1,2, Alexey A Gavrilov2, Daniil A Alexeyevsky3, Artem V Artemov4, Sergey V Razin1,2, Mikhail A Rubtsov1,5.
Abstract
Topoisomerase inhibitors are widely used in cancer chemotherapy. However, one of the potential long-term adverse effects of such therapy is acute leukemia. A key feature of such therapy-induced acute myeloid leukemia (t-AML) is recurrent chromosomal translocations involving AML1 (RUNX1) or MLL (KMT2A) genes. The formation of chromosomal translocation depends on the spatial proximity of translocation partners and the mobility of the DNA ends. It is unclear which of these two factors might be decisive for recurrent t-AML translocations. Here, we used fluorescence in situ hybridization (FISH) and chromosome conformation capture followed by sequencing (4C-seq) to investigate double-strand DNA break formation and the mobility of broken ends upon etoposide treatment, as well as contacts between translocation partner genes. We detected the separation of the parts of the broken AML1 gene, as well as the increased mobility of these separated parts. 4C-seq analysis showed no evident contacts of AML1 and MLL with loci, implicated in recurrent t-AML translocations, either before or after etoposide treatment. We suggest that separation of the break ends and their increased non-targeted mobility-but not spatial predisposition of the rearrangement partners-plays a major role in the formation of these translocations.Entities:
Keywords: AML1; KMT2A; MLL; RUNX1; chromosomal translocation; etoposide; t-AML; therapy-related AML; topoisomerase inhibitor-related leukemia; topoisomerase inhibitors
Mesh:
Substances:
Year: 2022 PMID: 36077220 PMCID: PMC9456246 DOI: 10.3390/ijms23179824
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Recurrent translocations in TI-related AML. The HUGO Gene Nomenclature Committee’s gene names are highlighted in bold.
| Gene | Translocation | Partner | References |
|---|---|---|---|
| t(8;21)(q22;q22) |
| [ | |
| t(3;21)(q26.2;q22) |
| [ | |
| t(1;21)(p36;q21) |
| [ | |
| t(9;11)(p22;q23) |
| [ | |
| t(4;11)(q21;q23) |
| [ | |
| t(19;11)(q13;q23) |
| [ | |
| t(11;19)(q23;p13.3) |
| [ | |
| t(11;16)(q23;p13) |
| [ |
Figure 1Example of program recognition of nuclei borders (A), chromosome territories (B), and upstream and downstream regions of the AML1 gene (C,D). Merged images from 3 channels are shown. Bold circles indicate the cells used for analysis (which passed all quality filters). The lower panels show an example of a cell with a “broken” AML1 allele (marked with arrows), one region of which is located outside the chromosomal territory visualized by a far-red whole chromosome painting probe (WCP). Probe 1 and probe 2 visualize upstream and downstream regions of the AML1 gene (Figure S1B).
Figure 2The distribution of pairwise distances within paired signals in control cells (A), in etoposide-treated cells (B) and cells treated with ionizing radiation (IR) (C). The red line separates the 99% quantile for the control experiment. The tail on the histogram of pairwise distances of signals in etoposide-treated cells is non-random with a confidence level of 0.997 (see Statistics in the Section 4).
Figure 3(A) Scatterplots reflect the distances between regions of one allele (x-axis) and the distance to the territory (y-axis, the value 0 reflects the border of the chromosome territory) for each AML1 region. Red and green colors reflect upstream and downstream regions of the AML1 break-apart FISH probe. (B) The upper scatter plot shows the data for the control cells, and the lower scatterplot depicts the etoposide-treated cells. N is the total number of dots in the scatterplot. (C) Percentage of alleles localized outside the chromosomal territory in control cells, as well as non-broken alleles and broken alleles in etoposide-treated cells (see statistic in Table S2).
Figure 44C-seq profiles of AML1 from untreated cells (blue) and from cells treated with etoposide (byzantium). The 4C-seq profiles of AML1 on chromosome 21 show cis-contacts (first pair of rows), and the 4C-seq profiles of AML1 on chromosomes 1, 3, and 8 show AML1 trans-contacts with chromosomes that bear AML1 translocation partners in TI-related AML (other pairs of rows). AML1 translocation partner genes are indicated by arrows. Data resolution is 500 kb. 4C-seq data are collected in Table S3.
Figure 54C-seq profiles of MLL from untreated cells (orange) and from cells treated with etoposide (green). The 4C-seq profiles of MLL on chromosome 11 show cis-contacts (first pair of rows), and the 4C-seq profiles of MLL on chromosomes 4, 9, and 19 show MLL trans-contacts with chromosomes that bear MLL translocation partners in TI-related AML (other pairs of rows). MLL translocation partner genes are indicated by arrows. Data resolution is 500 kb. 4C-seq data are collected in Table S3.